Content uploaded by Fred M Konikoff
Author content
All content in this area was uploaded by Fred M Konikoff on Dec 24, 2013
Content may be subject to copyright.
ORIGINAL ARTICLES
455
IMAJ • VOL
13
• August
2011
Background: The marijuana plant cannabis is known to have
therapeutic effects, including improvement of inflammatory
processes. However, no report of patients using cannabis for
Crohn’s disease (CD) was ever published.
Objectives: To describe the effects of cannabis use in
patients suffering from CD.
Methods: In this retrospective observational study we
examined disease activity, use of medication, need for
surgery, and hospitalization before and after cannabis use in
30 patients (26 males) with CD. Disease activity was assessed
by the Harvey Bradshaw index for Crohn’s disease.
Results: Of the 30 patients 21 improved significantly after
treatment with cannabis. The average Harvey Bradshaw
index improved from 14 ± 6.7 to 7 ± 4.7 (
P
< 0.001). The need
for other medication was significantly reduced. Fifteen of the
patients had 19 surgeries during an average period of 9 years
before cannabis use, but only 2 required surgery during an
average period of 3 years of cannabis use.
Conclusions: This is the first report of cannabis use in Crohn’s
disease in humans. The results indicate that cannabis may
have a positive effect on disease activity, as reflected by
reduction in disease activity index and in the need for other
drugs and surgery. Prospective placebo-controlled studies
are warranted to fully evaluate the efficacy and side effects
of cannabis in CD.
IMAJ
2011; 13: 455–458
Crohn’s disease, inflammatory bowel disease, cannabis,
marijuana
Treatment of Crohn’s Disease with Cannabis:
An Observational Study
Timna Naftali MD1, Lihi Bar Lev BA2, Doron Yablekovitz MD1, Elisabeth Half MD1 and Fred M. Konikoff MD1
1Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba affiliated with Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel
2Department of Psychology, Faculty of Social Sciences, Tel Aviv University, Ramat Aviv, Israel
ABSTRACT:
KEY WORDS:
The marijuana plant, Cannabis sativa, has been used
as a medicinal treatment for a variety of diseases [1].
Cannabinoids have been reported to alleviate neurological
conditions including multiple sclerosis-related symptoms such
as spasticity, pain, tremor and bladder dysfunction [2]. Other
neurological conditions, such as chronic intractable pain, dys-
tonic movement disorders, and Tourette’s syndrome were also
reported to be alleviated by cannabis use [3]. Cannabis has
been used to treat anorexia in AIDS and cancer patients [2,3].
In gastroenterology, cannabis has been used to treat anorexia,
emesis, abdominal pain, gastroenteritis, diarrhea, intestinal
inammation, and diabetic gastroparesis [4].
e cannabis plant contains over 60 dierent compounds,
which are collectively referred to as cannabinoids [5]; of them
Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
seem to be the most active. Cannabinoids have a profound
anti-inammatory eect, mainly through the CB2 receptor
[2]. Cell-mediated immunity was found to be impaired in
chronic marijuana users [6]. A potent anti-inammatory
eect of cannabis was observed in rodents [7]. Studying the
functional roles of the endocannabinoid system in immune
modulation reveals that it is involved in almost all major
immune events. Cannabinoids shi the balance of pro-
inammatory cytokines and anti-inammatory cytokines
towards the T helper cell type 2 proles (2 phenotype)
and suppress cell-mediated immunity, whereas humoral
immunity may be enhanced [8]. erefore, cannabinoids
may be used to treat various inammatory conditions
including rheumatoid arthritis. In a mouse model of colitis,
cannabinoids were found to ameliorate inammation [9].
Consequently, the non-conventional medical community
has recommended cannabis for patients with inammatory
bowel disease. However, there are no systematic reports of
the eects of cannabis on IBD. e aim of this study was to
describe the response of patients with Crohn’s disease who
have used cannabis to ameliorate their symptoms.
PATIENTS AND METHODS
is was a retrospective observational study. A voluntary
organization that distributes cannabis for legally authorized
medical use in Israel was contacted. We interviewed patients
with CD who had permission from the Ministry of Health to
receive cannabis for their symptoms. Patients were questioned
about the details of their disease, previous medical and surgi-
cal treatments, and the reason for using cannabis. Disease
activity before and aer cannabis use was estimated by the
Harvey Bradshaw index. All patients assessed their general
IBD = inflammatory bowel disease
CD = Crohn’s disease
ORIGINAL ARTICLES
456
IMAJ • VOL
13
• August
2011
well-being before and aer cannabis use on a Visual Analog
Scale. e scale ranged from 0, which represented “very poor
general well-being” to 10, indicating “excellent well-being.”
Whenever possible, medical documents were reviewed for
objective signs of disease severity, such as number of hospital
admissions and use of other drugs, particularly steroids. e
dose and form of administration of cannabis were docu-
mented. e study was approved by the institutional ethics
committee of our hospital.
RESULTS
irty patients with CD who were using cannabis were inter-
viewed. e average age was 36 years (range 21–65 years)
and four were female. One patient with CD had a history
of partial pancreatectomy for serous cystadenoma, one had
asthma and two had hypertension. All other patients were
generally healthy apart from their CD. Before the use of
cannabis, ve patients had undergone right hemicolectomy,
three had resection of the terminal ileum, two had resection
of a proximal section of the ileum, and three had drainage
of a perianal stula. One patient with severe colitis had a
total proctocolectomy with ileoanal anastomosis. Aer the
operation she developed perianal disease and the diagnosis
was changed from ulcerative colitis to Crohn’s disease. Of the
15 patients who had an operation before using cannabis, 2
(13%) required another surgery during an average time of 2
years while on cannabis. e average duration of disease was
11.3 years (range 1–41 years). Twenty patients with CD had
inammation of the terminal ileum, 5 had inammation of
the more proximal ileum and 8 had Crohn’s disease of the
colon. One patient had pouchitis. Crohn’s disease was stuliz-
ing in 10 patients, brostenotic in 5, and luminal in 15. Before
cannabis use, 27 patients had received 5-ASA (5-aminosali-
cylic acid), 26 received corticosteroids, 20 took thiopurines,
6 took methotrexate, and 12 took anti-tumor necrosis factor
antibodies. Of 30 patients, 16 smoked tobacco regularly, 3
smoked tobacco before using cannabis but stopped when
they started cannabis use, and 14 never smoked tobacco. Of
the three patients who stopped tobacco smoking, one did not
improve (Harvey Bradshaw score of 4 both before and aer
cannabis use), one improved signicantly (from 11 to 2), and
one improved slightly (from 9 to 7), Although tobacco smok-
ing is known to have a negative eect on Crohn’s disease,
these results do not indicate that smoking cessation in itself
had any eect on disease severity in our patients.
e indication for cannabis use was lack of response to
conventional treatment in 21 patients and chronic intractable
pain in 6. Another four patients smoked cannabis for recre-
ation and continued as they observed an improvement in their
medical condition. Most patients smoked cannabis in the form
of hand-rolled cigarettes (“joints”). Four patients inhaled the
smoke through water (“bong”), and one patient preferred to
consume it orally. Most smoked between one and three “joints”
a day, but one patient with chronic pain smoked seven joints a
day. Since one cigarette contains about 0.5 mg of THC, patients
were using 0.5–1.5 mg/day THC, with the exception of one
patient who was using 3.5 mg. e average duration of can-
nabis use was 2.14 years (range 3 months to 9 years). In 14
patients the duration of cannabis use was less than a year.
All patients stated that consuming cannabis had a positive
eect on their disease activity. is is also reected in the
Visual Analog Scale, which increased from 3.1 to 7.3. e
Harvey Bradshaw index decreased from 14 ± 6.7 to 7 ± 4.7
(P < 0.001) [Figure 1]. e mean number of bowel move-
ments decreased from eight to ve a day and the need for
other drugs was signicantly reduced [Table 1]. Of particular
interest is the observation that cannabis may have a steroid-
sparing eect, since the number of patients requiring steroid
treatment was reduced from 26 to 4. Fieen of the patients
had 19 surgeries during an average period of 9 years before
cannabis use, but only 2 required surgery during an aver-
age period of 3 years of cannabis use. In nine patients can-
nabis treatment did not induce a signicant improvement,
as reected by a change of less than 4 points in the Harvey
Bradshaw index. ree of these patients did not respond to
THC = Δ9-tetrahydrocannabinol
Average Range
Age (yrs) 36 21–65
Male/Female 26/4
Disease duration (yrs) 11.3 1–41
Disease phenotype 15 luminal, 10 fistulizing, 5 fibrostenotic
Duration of cannabis
consumption
2.1 yrs 3 mos–9 yrs
Amount consumed
(“joints”/day)
2.4 0.5–7
Joint = cigarette
Table 1. Patient characteristics
Figure 1. Harvey Bradshow index before and after cannabis use
30
25
20
15
10
5
0
1 11 13 15 17 19 21 23 25 27 293 5 7 9
Before cannabis
After cannabis
ORIGINAL ARTICLES
457
IMAJ • VOL
13
• August
2011
the ecacy of cannabis in Crohn’s disease. e restraint from
the use of an illegal drug may have played a role.
e observed benecial eect in this study may be due to
the anti-inammatory properties of cannabis, but additional
eects of cannabinoids may also play a role. Cannabinoids
inuence gastrointestinal motility and, in particular, have an
anti-diarrheal eect, as observed in mice injected with chol-
era toxin [12]. e central eect of cannabinoids may induce
a sensation of general well-being, which could contribute to
the feeling that cannabis use is benecial. However, this gen-
eral eect wears o with time as tolerance develops, while the
positive eect of cannabis on disease activity in our patients
was maintained for an average period of 3.1 years.
One of the reasons that cannabis is unappealing to many
patients is that it is administered by smoking. Smoking in
general is unacceptable to both medical professionals and
many patients. e negative eect of tobacco smoking on
Crohn’s disease is also well known. Several studies demon-
strated a dose-related adverse eect of cannabis on large
airway function, but not on small airway function, which is
compromised by tobacco smoking [13,14]. Smoking cannabis
is the preferred mode of consumption because upon smok-
ing, blood levels of cannabinoids rise rapidly and a central
eect is achieved quickly. However, an anti-inammatory
eect, especially in the gut, may be achieved equally well by
consuming cannabis orally.
Although many side eects were connected with cannabis
use, most of them were in people who consumed other drugs
and alcohol together with cannabis. When consumed alone,
the safety prole of cannabis is very good [15]. Wang et al.
[16] reviewed 31 studies of medical cannabis use and found
that 96% of 4779 adverse events were minor. e relative risk
for serious adverse events was 1.04, which was not dierent
between the placebo and study groups. Cannabinoids may
therefore be a potential addition to the currently limited
arsenal of medications used to treat IBD. On the other hand,
because the use of medical cannabis may be exploited by
drug abusers, extra caution is necessary before cannabis can
be recommended to patients. A placebo-controlled study is
needed to fully investigate the therapeutic value of cannabis
for the treatment of Crohn’s disease.
Acknowledgment
e authors would like to thank the Tikun Olam organization for
their help in conducting the study.
Corresponding author:
Dr. T. Naftali
Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba
44281, Israel
Phone: (972-9) 747-1045
Fax: (972-9) 744-1731
email: naftali@post.tau.ac.il
any other medical therapy, including TNF antagonists, and
are now awaiting surgery.
DISCUSSION
In this study, we describe 30 patients with CD for whom the
use of cannabis ameliorated disease activity and reduced the
need for other conventional medications. is is the largest
and, to the best of our knowledge, the rst reported series
of CD patients treated with cannabis. It is a retrospective
observational study and as such is not a replacement for a
prospective placebo-controlled study. ere may be a popula-
tion bias in the sense that some people may be more attracted
to the possibility of smoking cannabis than others. is may
explain the over-representation of young males in our study
population. Also, there may be patients who tried cannabis
and whose condition did not improve; they would be lost to
follow-up and are not represented in our study. However, the
benet reported by most of the patients in our study suggests
a possible signicant therapeutic potential. Due to the retro-
spective nature of our study there may be a bias in recalling
disease activity. However, several facts point to an objective
benet of cannabis use. e observed reduced use of steroids
(from 26 to 4 patients) [Table 2] and other drugs may point
to an objective benecial eect of cannabis. Whereas 25%
to 38% of operated Crohn’s disease patients are expected to
require a second operation within 5 years of the rst [11],
only 2 of 15 patients (13%) who had surgery before cannabis
consumption required surgery while consuming cannabis.
Larger numbers and longer follow-up are needed to verify
whether use of cannabis reduces the need for surgery.
e eects of cannabinoids on the immune system are
diverse and include modulating proliferation of B cells, T cells,
and natural killer cells, modulating production of antibodies
and cytokines, and regulating functions of NK cells, mac-
rophages, T helper cells, mast cells and dendritic cells [10].
Although anti-inammatory eects of cannabis have been
described previously, there are no systematic descriptions of
TNF = tumor necrosis factor
NK = natural killer
Drug Before After
No treatment None 9
5-ASA 27 5
Corticosteroids 26 4
Thiopurine 20 10
Methotrexate 6 0
TNF antagonist 12 4
5-ASA = 5-aminosalicylic acid
Table 2. Medical treatment before and after cannabis use (n=30)
ORIGINAL ARTICLES
458
IMAJ • VOL
13
• August
2011
receptor (CB(2)) protects against experimental colitis. Inamm Bowel Dis
2009; 11: 1678-85.
Dai Lu V, Kiran V, Richard I, et al. e cannabinergic system as a target for 10.
anti-inammatory therapies. Curr Topics Med Chem 2006; 6: 1401-26.
Whelan G, Farmer RG, Fazio VW, et al. 11. Recurrence aer surgery in Crohn's
disease. Relationship to location of disease (clinical pattern) and surgical
indication. Gastroenterology 1985; 88: 1826-33.
Izzo AA, Capasso F, Costagliola A, et al. An endogenous cannabinoid tone 12.
attenuates cholera toxin-induced uid accumulation in mice. Gastroenterology
2003; 125: 765-74.
Aldington S, 13. Williams M, Nowitz M, et al. Eects of cannabis on pulmonary
structure, function and symptoms. orax 2007; 62 (12): 1058-63.
Hancox RJ14. , Poulton R, Ely M, et al. Eects of cannabis on lung function: a
population-based cohort study. Eur Respir J 2010; 35 (1): 42-7.
Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and 15.
therapeutic uses of cannabis and cannabinoids. Anaesthesia 2001; 56: 1059-68.
Wang T, Collet JP, Shapiro S, et al. Adverse eects of medical cannabinoids: a 16.
systematic review. CMAJ 2008; 178 (13): 1669-78.
References
Wingerchuk D. Cannabis for medical purposes: cultivating science, weeding 1.
out the ction. Lancet 2004; 364: 315-16.
Baker D, Pryce G, Giovannoni G, et al erapeutic potential of cannabis. 2.
Lancet Neurol 2003; 2: 291-8.
Williamson EM, Evans FJ. Cannabinoids in clinical practice. 3. Drugs 2000; 60
(6): 1303-14.
Izzo AA, Camilleri M. Gastrointestinal and liver diseases: basic and clinical 4.
aspects: emerging role of cannabinoids. Gut 2008; 57: 1140-55.
Hall W, Solowij N. Adverse eects of cannabis. 5. Lancet 1998; 352: 1611-16.
Nahas G, Sucui-Foca N, Armand JP. Decrease of cellular immunity in hashish 6.
(marihuana) smokers. C R Acad Sci Hebd Seances Acad Sci D 1973; 277: 979-80.
Soa RD, Knobloch LC, Vassar HB. e anti-edema activity of various naturally 7.
occurring cannabinoids. Res Commun Chem Pathol Pharmacol 1973; 6: 909-18.
Pacici R, Zuccaro P, Pichini S, et al. Modulation of the immune system in 8.
cannabis users. JAMA 2003; 289: 1929-31.
Storr MA, Keenan CM, Zhang H, et al. Activation of the cannabinoid 2 9.
Many autoimmune diseases, including multiple sclerosis
(MS), are more prevalent in women. This, coupled with
prior findings implicating a role for the estrogen receptor
(ER) in MS, prompted Saijo et al. to uncover the underlying
molecular mechanisms. After determining that microglia,
resident myeloid cells in the brain, primarily express ERβ,
the authors showed that depending on the ligand, signaling
through ERβ could either induce or inhibit pro-inflammatory
gene expression. 17β-estradiol, which is more prevalent
in women, drove expression of pro-inflammatory genes,
whereas 5-androsten-3β,17β-diol (ADIOL) inhibited them.
This occurred because ADIOL, but not 17β-estradiol, led
to the recruitment of CtBP corepressor complexes, which
functioned with ERβ and the transcription factor AP-1 to shut
down pro-inflammatory gene expression. In women, this
pathway may be antagonized because of increased amounts
of 17β-estradiol, which competes with ADIOL for binding to
ERβ and does not induce the recruitment of CtBP. Synthetic
ligands that signaled similarly to ADIOL were protective
and therapeutic in a mouse model of MS, which suggests
that this pathway may be a useful target for therapeutic
intervention.
Cell
2011; 13: 584
Eitan Israeli
Capsule
Estrogen receptor's two faces
The immune system is constantly surveying the body for
signs of infection, but how can it distinguish viruses from
self? Viruses can be distinguished from self because their
nucleic acids contain specific characteristics, such as the
triphosphorylated RNA (PPP-RNA), that are not found in the
nucleic acids of host cells. The molecules that recognize
these viral structures, however, are still being identified.
Pichlmair and co-authors carried out a screen to identify
proteins that interact with PPP-RNA and identified several
members of the IFIT family of interferon-stimulated proteins.
In response to antiviral interferons, IFIT proteins formed
a molecular complex with other family members and RNA-
binding proteins. Subsequent biochemical and genetic
analysis focused on IFIT1 and found that, although it did not
appear to be involved in the initial detection of the virus, it
was highly induced in response to antiviral interferons and
was required for keeping viral growth in check in cultured
cells and in mice infected with vesicular stomatitis virus.
Although IFITs have been previously associated with inhi-
bition of protein translation, the authors presented data
consistent with IFIT1 functioning by sequestering viral nucleic
acids within the cell.
Nat Immunol
2011; 12: 10.1038/ni.2048
Eitan Israeli
Capsule
How the immune system can distinguish viruses from self?
“Experience is not what happens to a man; it is what a man does with what happens to him”
Aldous Huxley (1894-1963), British novelist, most famous for his classic
Brave New World
